INT22385

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1990
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 5.16
Pain Relevance 0.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Ptgir) signal transducer activity (Ptgir)
Anatomy Link Frequency
portal vein 2
plasma 1
endothelial cells 1
brain 1
lung 1
Ptgir (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 25 98.72 Very High Very High Very High
antagonist 40 93.28 High High
ischemia 10 77.20 Quite High
Angina 1 67.60 Quite High
anesthesia 6 63.52 Quite High
halothane 1 61.80 Quite High
corticosteroid 2 59.40 Quite High
cva 11 48.00 Quite Low
Pain 11 27.28 Quite Low
headache 6 26.80 Quite Low
Disease Link Frequency Relevance Heat
Thrombosis 2 100.00 Very High Very High Very High
Pulmonary Hypertension 294 98.04 Very High Very High Very High
Pressure Volume 2 Under Development 10 97.24 Very High Very High Very High
Coronary Artery Disease 8 97.16 Very High Very High Very High
Hypoxia 14 91.54 High High
Syndrome 20 90.68 High High
Increased Venous Pressure Under Development 46 88.82 High High
Hypothermia 3 82.40 Quite High
Acidosis 5 81.88 Quite High
Apoptosis 63 81.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results indicated that activation of a central type prostacyclin receptor attenuates ischemic brain damage.
Positive_regulation (activation) of prostacyclin receptor in brain
1) Confidence 0.41 Published 2002 Journal Brain Res. Section Abstract Doc Link 11792366 Disease Relevance 0.35 Pain Relevance 0.24
Five patients demonstrated increased levels of prostacyclin during clamping of the portal vein and four experienced significant hypotension at reperfusion.
Positive_regulation (levels) of prostacyclin in portal vein associated with pressure volume 2 under development
2) Confidence 0.36 Published 1990 Journal Nurse Anesth Section Abstract Doc Link 2285709 Disease Relevance 0.82 Pain Relevance 0.06
Five patients demonstrated increased levels of prostacyclin during clamping of the portal vein and four experienced significant hypotension at reperfusion.
Positive_regulation (increased) of prostacyclin in portal vein associated with pressure volume 2 under development
3) Confidence 0.36 Published 1990 Journal Nurse Anesth Section Abstract Doc Link 2285709 Disease Relevance 0.83 Pain Relevance 0.06
The results showed that Sustanon 250 administration increased plasma ANP levels, decreased TXA2 and increased PGI2 levels significantly, and thereby improved the TXA2/PGI2 imbalance in CHD patients (all P < 0.01).
Positive_regulation (increased) of PGI2 in plasma associated with coronary artery disease
4) Confidence 0.26 Published 1993 Journal Chin. Med. Sci. J. Section Abstract Doc Link 8032065 Disease Relevance 0.92 Pain Relevance 0.10
In patients with pulmonary hypertension, pulmonary endothelial cells have decreased expression of prostacyclin synthase89 and urinalysis demonstrates a decrease in stable prostacyclin metabolites.26
Positive_regulation (stable) of prostacyclin in endothelial cells associated with pulmonary hypertension
5) Confidence 0.04 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.63 Pain Relevance 0.12
Combination of sildenafil with an endothelin receptor antagonist (notably bosentan) has been recently validated in several trials, improving hemodynamic variables, exercise capacity, and quality of life in patients with IPAH or PAH unresponsive to monotherapy.131–133 Limited trials of treatment with bosentan and a prostacyclin agonist such as epoprostenol or iloprost have suggested this may be an effective combination.134,135 Inhaled prostacyclin and milrinone have also been postulated to work synergistically to reduce PVR.136
Positive_regulation (effective) of prostacyclin associated with pulmonary hypertension, antagonist and agonist
6) Confidence 0.04 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.42 Pain Relevance 0.13
Deletion of the PPRE elements from the promoter construct abolishes the promoter stimulating effect of cPGI2 or L-165041.
Positive_regulation (effect) of cPGI2
7) Confidence 0.03 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.27 Pain Relevance 0
In PAH, vascular remodeling and vasoconstriction are determined by an imbalance of the intracellularly synthesized factors.7 Experiments in rats exposed to monocrotaline and in hypoxic mice developing PAH have shown increased PGI2 synthase expression in the lung, partially antagonizing the rise in pulmonary arterial pressure.8,9 A deficiency of PGI2 synthase in remodeled pulmonary vasculature has been reported in patients suffering from severe PAH.10 Accordingly, exogenous PGI2 benefits patients with PAH by antagonizing the effects of vasoconstrictors such as thromboxane A2 and serotonine, which are increased in endothelial cells11 causing platelet activation and thrombosis.12 Prostacyclin also possesses positive inotropic effects resulting in an acutely increased cardiac output.13 Long-term improvements of cardiac output may in contrast be caused by anti-remodeling effects of PGI2.14
Positive_regulation (increased) of Prostacyclin in lung associated with pulmonary hypertension, hypoxia, increased venous pressure under development and thrombosis
8) Confidence 0.01 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2686263 Disease Relevance 0.92 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox